IMR Press / FBL / Volume 28 / Issue 9 / DOI: 10.31083/j.fbl2809215
Open Access Original Research
EPO rs1617640 A>C is a Protective Factor for Chronic Obstructive Pulmonary Disease: A Case Control Study
Show Less
1 Institute of Basic Medicine, Institute of Public Health, Gansu University of Chinese Medicine, 730000 Lanzhou, Gansu, China
2 The State Key Lab of Respiratory Disease, The First Affiliated Hospital, Institute of Public Health, Guangzhou Medical University, 511436 Guangzhou, Guangdong, China
3 Department of Respiratory Medicine, SSL Central Hospital of Dongguan City, 523326 Dongguan, Guangdong, China
4 Department of Respiratory and Critical Care Medicine, Dongguan Binwan Central Hospital, 523903 Dongguan, Guangdong, China
5 Department of Respiratory and Critical Care Medicine, Shenzhen Longhua District Central Hospital, 518110 Shenzhen, Guangdong, China
6 Centre for Medical Laboratory Science, the Affiliated Hospital of Youjiang Medical University for Nationalities, 533099 Baise, Guangxi, China
7 Department of Respiratory Medicine, Affiliated Hospital of Gansu University of Chinese Medicine, 730000 Lanzhou, Gansu, China
*Correspondence: wxh@gszy.edu.cn (Xinhua Wang); jcLu@gzhmu.edu.cn (Jiachun Lu)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(9), 215; https://doi.org/10.31083/j.fbl2809215
Submitted: 8 February 2023 | Revised: 29 March 2023 | Accepted: 11 April 2023 | Published: 24 September 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: The occurrence and development of chronic obstructive pulmonary disease (COPD) are regulated by environmental and genetic factors. In hypoxia, Erythropoietin (EPO) satisfies the body’s need for oxygen by promoting the production of red blood cells. Hypoxia was proven to be a common physiological condition in COPD progression and associated with many complications. Some studies have found that EPO is involved in the development of COPD. But the mechanism has not been fully proven. Methods: We conducted a case-control study enrolled 1095 COPD patients and 1144 healthy controls in Guangdong Province to evaluate the association between EPO polymorphisms (rs1617640 A>C, rs507392 A>G, rs564449 G>T) and COPD susceptibility. 872 participants from southern Gansu Province were recruited to verify the effect of EPO polymorphisms on lung function. Results: EPO rs1617640 C allele reduced COPD susceptibility in southern Chinese significantly (AC vs. AA: adjusted Odds ratio (OR) = 0.805, 95% CI = 0.669–0.969; AC+CC vs. AA: adjusted OR = 0.822, 95% CI = 0.689–0.980). However, there was no association between rs507392 A>G and rs564449 G>T polymorphisms and COPD susceptibility (p > 0.05). We further observed that the rs1617640 C allele was associated with higher FEV1 and FVC in Guangdong and Gansu populations significantly (both p < 0.05). In brief, the level of FEV1 and FVC increased with the C allele number. We modeled the relative risk for men and women, in which the population-attributable risks chances were 0.449 (0.258–0.641) and 0.262 (0.128–0.396) respectively. In this model, smoking status, coal as fuels, education level, and rs1617640 A>C were finally retained for males, while smoking status, biomass as fuels, and1617640 A>C were retained for females. In the end, using the method developed by Gail and Bruzzi, we fitted a 10-year absolute risk model for southern Chinese with different individual relative risks, which was presented as a table. Conclusions: In conclusion, this study found that EPO rs1617640 A>C polymorphism is associated with COPD susceptibility in southern Chinese, and the C allele was associated with better lung function. In addition, it could also be considered a genetic marker associated with environmental factors to predict the absolute 10-year risk of COPD in southern Chinese.

Keywords
COPD
EPO
polymorphism
susceptibility
absolute risk
Funding
2017YFC0907202/National Key Research and Development Project of China
81872694/National Natural Science Foundation of China
82173609/National Natural Science Foundation of China
2017BT01S155/Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
A2020324/Guangdong Medical Science and Technology Research Fund Project
81460123/National Natural Science Foundation of China
2018GXNSFAA281187/Guangxi Natural Foundation
82260889/National Natural Science Foundation of China
202103000073/the Science and Technology Project of Guangzhou
Figures
Fig. 1.
Share
Back to top